<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576705</url>
  </required_header>
  <id_info>
    <org_study_id>IJL-AFHT-TH10</org_study_id>
    <nct_id>NCT01576705</nct_id>
  </id_info>
  <brief_title>Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children</brief_title>
  <acronym>ACTHYF</acronym>
  <official_title>Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Jerome Lejeune</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ascopharm (CRO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Effi-stat (CRO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AnticipSante (CRO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LC2 (CRO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BIOMNIS Central laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMR INSERM 1124</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire de Biochimie Biologie Moléculaire Nutrition Métabolisme CHU Brabois (Unité Inserm 954)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Jerome Lejeune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the following in very young children with Down syndrome:

        -  the efficacy of systematic treatment with L-thyroxine at controlled doses (clinically
           and by ultrasensitive thyreostimulating hormone (TSH) assay),

        -  the efficacy of systematic folinic acid treatment at a dose of 1 mg/kg/o.i.d,

        -  any interaction between these two treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">December 14, 2017</completion_date>
  <primary_completion_date type="Actual">December 14, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GMDS ( Griffiths Mental Development Scale)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BL (Brunet Lezine revised scale)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Down Syndrome</condition>
  <arm_group>
    <arm_group_label>Thyroxin + folinic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroxin+folinic acid placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroxin placebo+ folinic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroxin placebo+ folinic acid placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thyroid hormone and folinic acid</intervention_name>
    <description>thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
    <arm_group_label>Thyroxin + folinic acid</arm_group_label>
    <arm_group_label>Thyroxin+folinic acid placebo</arm_group_label>
    <arm_group_label>Thyroxin placebo+ folinic acid</arm_group_label>
    <arm_group_label>Thyroxin placebo+ folinic acid placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with a karyotype demonstrating homogeneous, free or Robertsonian translocation
             trisomy 21

          -  patient having undergone a cardiac ultrasound not demonstrating any severe heart
             disease

          -  patient aged 6 to 18 months at inclusion

        Exclusion Criteria:

          -  congenital hypothyroidism

          -  hypothyroidism demonstrated by laboratory tests (TSH &gt; 7mUI/l)

          -  presenting or having presented hyperthyroidism

          -  presenting or having presented leukaemia

          -  presenting or having presented West syndrome or any other form of epilepsy or unstable
             neurological disease

          -  presenting or having presented signs of central nervous system distress: stroke,
             postoperative hypoxia, meningitis)

          -  presenting severe heart disease on cardiac ultrasound, with haemodynamic effects

          -  presenting non-controlled cardiac arrhythmia

          -  Apgar &lt; 7 to 5 min at birth

          -  Gestational age &lt; 231 days (33 gestation weeks)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clotilde MIRCHER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jerome Lejeune, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franck STURTZ, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Biochemistry and Molecular Genetics, Limoges University, Limoges, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jerome Lejeune</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.institutlejeune.org/</url>
    <description>Institut Jerome Lejeune</description>
  </link>
  <reference>
    <citation>Blehaut H, Mircher C, Ravel A, Conte M, de Portzamparc V, Poret G, de Kermadec FH, Rethore MO, Sturtz FG. Effect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status. PLoS One. 2010 Jan 11;5(1):e8394. doi: 10.1371/journal.pone.0008394.</citation>
    <PMID>20084109</PMID>
  </reference>
  <reference>
    <citation>van Trotsenburg AS, Kempers MJ, Endert E, Tijssen JG, de Vijlder JJ, Vulsma T. Trisomy 21 causes persistent congenital hypothyroidism presumably of thyroidal origin. Thyroid. 2006 Jul;16(7):671-80.</citation>
    <PMID>16889491</PMID>
  </reference>
  <reference>
    <citation>van Trotsenburg AS, Vulsma T, van Rozenburg-Marres SL, van Baar AL, Ridder JC, Heymans HS, Tijssen JG, de Vijlder JJ. The effect of thyroxine treatment started in the neonatal period on development and growth of two-year-old Down syndrome children: a randomized clinical trial. J Clin Endocrinol Metab. 2005 Jun;90(6):3304-11. Epub 2005 Mar 8.</citation>
    <PMID>15755847</PMID>
  </reference>
  <reference>
    <citation>Ellis JM, Tan HK, Gilbert RE, Muller DP, Henley W, Moy R, Pumphrey R, Ani C, Davies S, Edwards V, Green H, Salt A, Logan S. Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial. BMJ. 2008 Mar 15;336(7644):594-7. doi: 10.1136/bmj.39465.544028.AE. Epub 2008 Feb 21.</citation>
    <PMID>18296460</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Down syndrome</keyword>
  <keyword>Young children</keyword>
  <keyword>Psychomotor development</keyword>
  <keyword>Thyroid hormone</keyword>
  <keyword>Folinic acid</keyword>
  <keyword>Psychometric tests</keyword>
  <keyword>GMDS</keyword>
  <keyword>Griffiths</keyword>
  <keyword>Genetic factors</keyword>
  <keyword>Biochemical factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Down Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

